I de åbne perioder i studie I, II og III opretholdt patienterne en forbedring i fysisk funktion gennem henholdsvis 48, 24 og 18 måneder.
During the open-label period of Studies I, II, and III, the improvement in physical function has been maintained through 48, 24, and 18 months, respectively.